Krystal Biotech Q2 net income rises 43% to $54.8 million; revenue climbs 24% to $119.2 million
KRYS•Second-quarter results
Krystal Biotech posted 2Q net income of $54.8 million, or $1.79 per diluted share, up from $38.3 million a year earlier.
Product revenue rose 24% year over year to $119.2 million, with gross margin at 95%.
Cash position, guidance and pipeline updates
Cash and investments totaled $1.1 billion at quarter-end; FY 2026 non-GAAP R&D and SG&A expense guidance was $175 million-$195 million.
VYJUVEK logged $965.9 million in global revenue since launch, with more than 730 reimbursement approvals and over 640 unique U.S. prescribers.
Management flagged multiple clinical readouts in 2H 2026; VYJUVEK launches in Spain and Italy remain targeted before year-end.
